The Impact of Panel Reactive Antibodies and Different Desensitization Methods on Pediatric Allogeneic Hematopoietic...

Area of Science:

• Immunology
• Hematology
• Transplantation medicine

Background:

• Highly sensitized patients with panel reactive antibodies (PRAs) before hematopoietic stem cell transplantation (HSCT) face increased primary graft failure risk.
• Understanding the impact of PRAs on HSCT outcomes is crucial for managing highly sensitized pediatric patients.

Purpose of the Study:

• To investigate the association between PRAs and engraftment, graft-versus-host disease (GVHD), and survival in pediatric HSCT.
• To compare outcomes between PRA-positive and PRA-negative pediatric patients undergoing HSCT.

Main Methods:

• A comparative study involving 43 PRA-positive and 42 PRA-negative pediatric patients.
• Assessment of graft failure, acute GVHD, viral infections, and survival rates.
• Subgroup analysis of PRA-positive patients based on treatment modality (steroid-only vs. combination therapy).

Main Results:

• No significant differences in graft failure, acute GVHD, or viral infections between PRA-positive and PRA-negative groups.
• The PRA-positive subgroup showed no difference in graft failure or viral infection rates between treatment modalities.
• Acute grade 3-4 GVHD was significantly higher in the steroid-only treatment group compared to combination therapy within the PRA-positive cohort.
• 100-day overall survival rates were comparable: 90.2% for PRA-positive and 90.4% for PRA-negative patients.

Conclusions:

• PRAs did not adversely affect engraftment, viral infections, or overall survival in this pediatric HSCT cohort.
• Treatment strategies for desensitization, including plasmapheresis, steroids, rituximab, or combination therapies, are vital for PRA-positive patients.
• Tailored, patient-specific treatment modalities before HSCT can enhance success rates in sensitized individuals.